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Abstract
A reversed-phase high-performance liquid chromatography assay was developed and validated to determine plasma and
brain lamotrigine concentrations allowing pharmacokinetic–pharmacodynamic studies of this new antiepileptic drug in
patients and laboratory animals. Lamotrigine and its internal standard were extracted, under alkaline conditions, from plasma
and brain homogenate, into ethyl acetate; brain proteins were previously precipitated with trichloroacetic acid. The method
was linear between 0.1 and 15.0 mg/ l for plasma, with a detection limit of 0.008 mg/ l, and between 0.1 and 5.0 mg/ l for
brain homogenate, with a detection limit of 0.023 mg/ l. The method proved to be simple, useful and appropriate, not only
for clinical and experimental research, but also for routine monitoring of lamotrigine concentrations in patients. Ó 2001
Elsevier Science B.V. All rights reserved.
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1. Introduction carbamazepine, in that any of these three drugs acts
by blocking the voltage-dependent sodium channels
Lamotrigine (LTG), an antiepileptic agent chemi- and thus prolonging their inactivated state and
cally unrelated to other anticonvulsants stabilising the presynaptic membrane. Consequently
(phenyltriazine derivative), is a new generation an- LTG acts in particular to prevent the release of
tiepileptic drug which has shown to be effective excitatory neurotransmitters [3,4].
against partial and secondarily generalized tonic– Although the use of LTG in clinical practice is
clonic seizures either on adjunctive treatment in reasonably well tolerated by patients, the resulting
patients with refractory epilepsy or when received as benefits of its administration are subject to a more
monotherapy [1,2]. The mechanism of action of LTG complex evaluation, given a considerable inter-pa-
is, nevertheless, comparable to that of phenytoin and tient variability observed in relation to the dosage
required to obtain an adequate therapeutic response.
There seems to exist a linear relationship between
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concentration and the induced pharmacological re- over time, to be able to establish the relationship
sponse inter-relate remains unknown [2,5]. The between the two types of curve [10–14].
possible sources of variability, in the light of current Several chromatographic methods for the determi-
knowledge regarding the kinetic profile of LTG, may nation of LTG concentration in human serum/plas-
have their origin in the transposition of the blood– ma have been reported [6,15–29]. However, consid-
brain barrier and/or in the intrinsic variability associ- ering the concentration ranges studied by these
ated with its mechanism of action. Tentative target methods, they do not seem adequate for clinical
ranges of 1–4 mg/ l have been proposed, but sub- research as described, seeing that it requires not only
sequent observations have indicated that some pa- a wide concentration range but also a very low limit
tients may tolerate much higher therapeutic con- of detection. On the other hand, in spite of its
centrations (.10 mg/ l) without clinical toxicity relevance for experimental research, very few meth-
[2,6]. Therefore, it seems evident that further studies ods exist for the determination of LTG simultaneous-
are required to assess the relationship between ly in various biological fluids, and only one of them
plasma concentration and clinical effect of LTG. has been proposed for the determination of LTG in
Furthermore, although most views concerning blood and brain [30].
fundamental mechanisms of human epileptic phe- Therefore, in the present paper, a sensitive and
nomena derived from investigations carried out on specific reversed-phase high-performance liquid
experimental animal models, research on patients chromatography (HPLC) method, with a wide con-
with epilepsy is essential to validate the relevance of centration range, was developed and validated to
those data. Nevertheless direct examination of the quantify LTG in plasma and in rat brain homogenate,
epileptic human brain has become very feasible in making it suitable not only for clinical and ex-
recent years, experimental paradigms are severely perimental research, but also for therapeutic drug
limited by ethical and logistical reasons. Thus, it monitoring.
seems that both goals are best met by designing
parallel investigations involving patients and ex-
perimental animals [7]. 2. Experimental
The investigation in patients is now facilitated by
the new clinical techniques that exist in association 2.1. Reagents
with the surgical treatment of epilepsy [7]. Long-
term video electroencephalographic (VEEG) moni- Lamotrigine BW430C78 [3,5-diamino-6-(2,3-
toring is one of those new tools, widely accepted as a dichlorophenyl)-1,2,4-triazine] and its internal stan-
cornerstone of the advanced diagnostic, especially in dard (I.S.) BW725C78 [3,5-diamino-6-(2-methoxy-
the management of patients who are candidates for phenyl)-1,2,4-triazine] (structural analogue) refer-
epilepsy surgery [8]. This technique of seizure ence materials were kindly provided by Wellcome
recording is frequently associated with medication Research Laboratories (Cardiff, UK) (Fig. 1). Ethyl
discontinuing, one of the strategies used to precipi- acetate, methanol (HPLC grade), sodium chloride,
tate seizures. Additionally, the use of laboratory sodium hydroxide, sodium phosphate monobasic and
animals may improve the understanding of the sodium phosphate dibasic dihydrate, trichloroacetic
relationship between drug in the blood and drug in acid and triethylamine were purchased from Merck
the brain. In fact, by necessitating the crossing of the (Darmstadt, Germany). Human plasma was kindly
blood–brain barrier in order to exercise its therapeu- provided by the Portuguese Oncology Institute blood
tic effect, the basis for the interpretation of the bank (Coimbra, Portugal).
plasma levels of LTG requires that these levels
reflect the drug concentrations at the neuronal sites 2.2. Apparatus
of action [9]. From this perspective, the neurophar-
mocokinetic characterization of LTG would neces- A BAS-480 Liquid Chromatograph equipped with
sarily have to include a parallel study of the evolu- a PM-80 pump, a Rheodyne manual injector with a
tion of concentrations in the blood and in the brain 50-ml loop, a BAS UV-116 UV–Vis detector and a
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2.3. Calibration
A stock standard of lamotrigine (100 mg/ l) was
prepared by dissolving 10 mg of BW430C78 in 100
ml of methanol. An intermediate standard (10 mg/ l)
was prepared by diluting the stock standard (1:10)
with plasma or rat brain homogenate. Another inter-
mediate standard (1 mg/ l) was prepared by diluting
appropriately the 10 mg/ l intermediate standard
(1:10). Standard curves were prepared by addition of
the adequate intermediate standard to a blank plasma
or blank brain homogenate to produce final con-
centrations of 0.1, 0.5, 2.5, 5.0, 10.0 and 15.0 mg/ l
for plasma or 0.1, 0.5, 1.0, 3.0 and 5.0 mg/ l for brain
homogenate. A stock solution (100 mg/ l) of the I.S.
was prepared by dissolving 10 mg of BW725C78 in
100 ml of methanol. An intermediate standard (40
mg/ l for plasma and 20 mg/ l for brain homogenate)
was prepared by diluting adequately the stock solu-
tion with methanol.
2.4. Extraction
Plasma sample extraction was based on the meth-
od presented by Fraser et al. [20] and Sallustio and
Morris [26]. The plasma (1 ml) was introduced into
a 10-ml glass tube and 100 ml of the 40 mg/ l
internal standard solution were added. After that, 1
ml of 2 M NaOH was added in order to assure that
the whole LTG would be in the molecular form, the
only form capable of passing into the organic phase.Fig. 1. Chemical structures of lamotrigine (LTG) and its internal
standard (I.S.). The sample was mixed briefly (10 s) by vortex and 5
ml of ethyl acetate were added. The tube was
capped, vortexed for 10 s and then mixed on a
horizontal shaker at 400 oscillations /min for 10 min
BAS DA-5 Chromatography Control and Data Sys- before centrifugation at 1585 g for a further 10 min
tem Interface (all from Bioanalytical Systems, West at 158C. The upper organic layer was transferred to a
Lafayette, IN, USA) were used for analysis. clean 10-ml conical glass tube and evaporated to
Chromatographic separation was carried out on a dryness under a stream of nitrogen in a heating block
LiChrospher 100 RP-18 (5 mm) LiChroCART 125-4 at 458C. The residue was reconstituted with 200 ml
(Merck) for 10 min. The mobile phase, consisting of of mobile phase and injected into the HPLC system.
35.0% methanol, 64.7% 0.1 M potassium dihydrogen For brain tissue preparation, the total rat brain was
phosphate solution and 0.3% triethylamine, was removed and homogenized with a 5 ml /g physiologi-
pumped at a flow-rate of 1.0 ml /min. The prepared cal buffer (phosphate buffer; pH 7.4) in a glass
mobile phase was filtered through a 0.45-mm Milli- homogenizer in an ice-cold bath. The homogenate (1
pore filter and degassed in an ultra-sonicator bath. ml) was inserted into a conical glass tube and 100 ml
The elution was performed at room temperature. The of the 20 mg/ l internal standard solution were added.
detector was set at 306 nm. For deproteinization, 100 ml of a 20% trichloroacetic
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acid solution were added followed by centrifugation or I.S. only by assaying five replicates for each
at 1585 g for 10 min at 158C. The supernatant concentration on the same day [18,19,34].
obtained was transferred to a 10-ml glass tube and In order to study the specificity of the present
submitted to a liquid–liquid extraction into ethyl method, six independent blank human plasma and rat
acetate after basification as described for plasma. brain homogenate samples were subjected to the
same sample processing and analysed. Because LTG
2.5. Validation is usually used in combination with other drugs in
human therapy, for selectivity evaluation, several
The method was validated according to the exist- potential interfering drugs were studied using the
ing information [31,32], consisting of the study of specified conditions: carbamazepine, phenytoin, val-
the reliability parameters: linearity, sensitivity, preci- proic acid, phenobarbital, primidone, vigabatrin,
sion, accuracy, recovery, specificity, selectivity and gabapentine, clobazam, clonazepam, midazolam and
stability. paracetamol. The chromatograms obtained were
The linearity was tested between 0.1 and 15.0 compared with the typical lamotrigine chromato-
mg/ l for plasma and 0.1 and 5.0 mg/ l for brain grams.
homogenate analysis. For the inter-day assay the Stability samples were freshly prepared by adding
standards were prepared over a 5-day period, while a known amount of LTG to a drug-free matrix and
the intra-day assay was performed for 1 day by stored in a refrigerator (48C) and in a freezer
analysing each concentration 5 times. Calibration (2258C). The evaluation was performed by assaying
data were plotted as a graph of LTG:I.S. peak area five replicates on each day.
ratio versus LTG concentration. The plot was sub-
jected to a weighted linear regression analysis with
the inverse of the concentration squared as the 3. Results
weighting factor. The data obtained were used for
the subsequent study of the validation parameters. 3.1. Chromatography, specificity and selectivity
The limit of detection (LOD) and the limit of
quantification (LOQ) of the analytical technique Typical chromatograms of human plasma and rat
were determined through the following equation brain homogenate extracts are shown in Figs. 2 and
C 5 K*S /b, where C is the LOD or the LOQ 3, respectively. Mean retention times for LTG and itsL B L
expressed in concentration, K takes the value of 3 for I.S. were 6.9 and 2.3 min, respectively. The lack of
LOD and 10 for LOQ, as per the recommendation of response in blank plasma and brain homogenate was
the International Union of Pure and Applied Chemis- demonstrated. The following drugs, usually used in
try (IUPAC), b is the slope of the calibration plot, co-administration with lamotrigine, were shown not
and an estimate of the standard deviation of the to interfere using the specified conditions: carbamaz-
blank, S , is given by the standard deviation of the epine, phenytoin, valproic acid, phenobarbital, primi-B
intercept, a (S ) [33]. done, vigabatrin, gabapentine, clobazam,a
Recovery samples were prepared by adding known clonazepam, midazolam and paracetamol.
amounts of LTG and/or internal standard to drug-
free plasma or brain homogenate. Drug peak area / 3.2. Linearity and sensitivity
internal standard peak area ratios after extraction of
the spiked sample were compared with the corre- The inter-day weighted linear regression equation
sponding ratios obtained after direct injection of of the plasma curve between 0.1 and 15.0 mg/ l was
non-extracted standard solutions. In this direct in- Y(A /A )50.2636X(conc. mg/ l)10.0067, with theI.S.
jection analysis, which was considered as the 100% value 0.995 for the correlation coefficient, (r value);
of recovery, the internal standard was added to the for the intra-day assay it was Y(A /A )5I.S.
solution samples just before injection into the col- 0.2804X(conc. mg/ l)20.0049, with r50.999. The
umn. This procedure evaluated the recovery of inter-day weighted linear regression equation of the
samples containing LTG in the presence of the I.S. brain homogenate curve between 0.1 and 5.0 mg/ l
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Fig. 2. Typical chromatograms of extracted human plasma: (A) human drug-free plasma; (B) human plasma spiked with lamotrigine
(conc.52.5 mg/ l; t 56.7 min) and internal standard (conc.54.0 mg/ l; t 52.3 min); (C) plasma sample from a patient treated withr r
lamotrigine (conc.510.6 mg/ l; t 56.7 min).r
was Y(A /A )50.2632X(conc. mg/ l)10.0029, with mg/ l and the limit of quantification LOQ was 0.030I.S.
r50.993; for the intra-day assay it was Y(A /A )5 mg/ l; in brain homogenate, the LOD calculatedI.S.
0.2661X(conc. mg/ l)10.0064, with r50.991. reached the value of 0.023 mg/ l and the LOQ was
The goodness of fit was confirmed by performing 0.078 mg/ l.
a chi-squared test. The weighted residual sum of
2
squares should, if the plot is linear, have a x 3.3. Accuracy and precision
distribution with (n22) degrees of freedom [33,35].
This assessment revealed a highly significant good- A summary of the results on precision and accura-
2 2
ness of fit seeing that x ,x . cy as derived from the measured concentrations forexp tab
In plasma, the lowest LOD calculated was 0.008 the validation samples when using the plasma con-
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nominal and experimental concentrations also re-
vealed no statistical difference between them (P.
0.05), which confirmed the accuracy of the method.
For brain homogenate, the dispersion around the
mean value did not exceed 15% coefficient of
variation and 20% for LOD (precision), and the
mean value was within 615% of the actual value
(accuracy), as recommended by the Washington
criteria [31]. The paired comparison between nomi-
nal and experimental concentrations also revealed no
statistical difference between them (P.0.05), which
also confirmed the accuracy of the method. A
summary of the results on precision and accuracy as
derived from the measured concentrations for the
validation samples when using the brain homogenate
concentration range between 0.1 and 5.0 mg/ l is
given in Table 2.
3.4. Recovery
The mean recovery of lamotrigine from plasma inFig. 3. Typical chromatograms of extracted rat brain homogenate:
the conditions of the assay between 0.1 and 15.0(A) rat drug-free brain homogenate; (B) rat brain homogenate
sample from a rat injected i.p. with lamotrigine at a dose of 10 mg/ l was found to be consistent over the evaluated
mg/kg (conc.50.6 mg/ l; t 56.1 min) and spiked with internalr concentration range and was 82.0567.46%
standard (conc.52.0 mg/ l; t 52.1 min).r (mean6SD) (Table 3). The average recovery of the
internal standard was 86.1469.26%.
centration range between 0.1 and 15.0 mg/ l is given For brain homogenate analysis between 0.1 and
in Table 1. The mean coefficients of variation were 5.0 mg/ l, the mean recovery of lamotrigine was also
4.02% for intra-day and 6.97% for inter-day analy- found to be consistent over the evaluated concen-
ses. The bias varied between 23.63 and 3.46% for tration range and was 87.16612.82% (mean6SD)
the intra-day assay and 23.79 and 1.82% for the (Table 4). The average recovery of the internal
inter-day assay. The paired comparison between standard was 75.2467.10%.
Table 1
aSummary of precision (% C.V.) and accuracy (% bias) of the analytical method for lamotrigine determination in plasma (n530)
C AssayNominal
(mg/ l) Intra-day Inter-day
b bC C.V. Bias C C.V. BiasMeasured Measured
(mg/ l) (%) (%) (mg/ l) (%) (%)
0.1 0.1060.003 3.12 0.28 0.1060.017 13.45 20.33
0.5 0.4960.023 4.88 22.33 0.5160.017 3.18 1.44
2.5 2.5760.049 1.93 2.73 2.5560.108 4.22 1.82
5.0 5.1760.114 2.21 3.46 5.0760.504 9.88 1.46
10.0 9.9560.515 5.19 20.48 9.9560.718 7.20 20.52
15.0 14.4660.983 6.81 23.63 14.4360.561 3.88 23.79
Mean – 4.02 0.004 – 6.97 0.013
a C , nominal concentration; C , measured concentration; C.V., coefficient of variation.Nominal Measured
b Mean6standard deviation.
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Table 2
aSummary of precision (% C.V.) and accuracy (% bias) of the analytical method for lamotrigine determination in brain homogenate (n525)
C AssayNominal
(mg/ l) Intra-day Inter-day
b bC C.V. Bias C C.V. BiasMeasured Measured
(mg/ l) (%) (%) (mg/ l) (%) (%)
0.1 0.1060.021 16.48 0.68 0.1060.022 19.66 20.63
0.5 0.5060.042 7.98 20.68 0.5260.027 5.00 4.83
1.0 0.9660.044 4.54 24.38 0.9660.043 4.45 23.70
3.0 2.9460.124 4.19 22.08 2.9360.069 2.33 22.21
5.0 5.3360.490 9.14 6.67 5.0860.236 4.64 1.65
Mean – 8.46 0.045 – 7.22 20.012
a C , nominal concentration; C , measured concentration; C.V., coefficient of variation.Nominal Measured
b Mean6standard deviation.
Table 3 months for plasma standards but only for 14 days for
Absolute recovery (%) of lamotrigine in spiked human plasma in brain homogenate standards. The results revealedathe presence of the internal standard (I.S.54.0 mg/ l) lamotrigine stability during the studied periods.
C n Recovery (%)Nominal
(mg/ l) Mean6SD C.V. (%)
4. Discussion2.5 5 83.6764.49 5.37
5.0 5 79.766.51 8.17
15.0 5 82.78611.02 13.31 In the present paper, a reversed-phase liquid
chromatographic assay was developed and validatedMean 2 82.0567.46 9.09
for LTG quantification in plasma and brain homoge-a C , nominal concentration; Mean6SD, mean6standardNominal
nate. The method involves an ordinary reversed-deviation; C.V., coefficient of variation; n, number of samples.
phase HPLC system with very simple chromato-
graphic conditions. A liquid–liquid extraction is
performed before column separation. Relative short3.5. Stability
time analysis is required (10 min). The UV detection
at 306 nm provides excellent specificity, eliminatingLamotrigine in plasma and in brain homogenate
most of the interference from plasma and brainappeared to be stable when stored in a refrigerator
homogenate. There was no chromatographic interfer-(48C) for 4 and 3 days, respectively. The study in the
ence from other commonly administered anticonvul-freezer (2258C) was performed during a period of 8
sants.
The accuracy of the method at the low end of the
Table 4
range was improved by using the appropriate weight-Absolute recovery (%) of lamotrigine in spiked rat brain homoge-
a ed scheme. In fact, when the range in data values isnate in the presence of the internal standard (I.S.52.0 mg/ l)
somewhat larger, the variance of each data point
C n Recovery (%)Nominal might be quite different (heteroscedasticity). A sim-
(mg/ l) Mean6SD C.V. (%) ple and effective way to homogenize the variance of
1.0 5 74.2768.12 10.94 responses across a concentration range is to use
3.0 5 98.6064.35 4.41 weighted least-squares linear regression [33,36–38].
5.0 5 88.62610.78 12.16 As well as the accuracy, the sensitivity of the method
Mean – 87.16612.82 14.70 was improved. Under the experimental conditions
a described, the lowest detection limit of plasmaC , nominal concentration; Mean6SD, mean6standardNominal
deviation; C.V., coefficient of variation; n, number of samples. lamotrigine concentration calculated was 0.008 mg/ l,
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